Jean Franchi
About Jean Franchi
Jean Franchi is a seasoned Chief Financial Officer with over 30 years of experience in finance leadership within the biotechnology sector, having significantly contributed to corporate growth and major financial transactions.
Jean Franchi Chief Financial Officer
Jean Franchi currently serves as the Chief Financial Officer. With a career spanning over three decades, Franchi brings extensive finance leadership experience, particularly within the biotechnology sector. Her latest role prior to the current position was as the Chief Financial Officer at Replimune, where she demonstrated notable achievements in financial strategy and funding.
Jean Franchi Educational Background
Jean Franchi holds a Bachelor's degree in Business Administration from Hofstra University. This foundational education has underpinned her successful career in finance, providing her with the knowledge and skills needed to navigate the complexities of financial management in the biotechnology industry.
Jean Franchi Finance Leadership Expertise
Jean Franchi has accumulated over 30 years of finance leadership expertise, predominantly in the biotechnology sector. She has held significant roles in both public and private companies, where she has contributed to financial strategy, fundraising, and corporate finance. Her extensive experience includes tenures as Chief Financial Officer at Replimune, Merrimack Pharmaceuticals, Dimension Therapeutics, and Good Start Genetics.
Jean Franchi Achievements at Replimune
During her tenure at Replimune, Jean Franchi helped raise over $750 million through multiple financing rounds and non-dilutive debt arrangements. Her efforts significantly strengthened the company's financial position, enabling ongoing research and development activities.
Jean Franchi Role at Genzyme
Jean Franchi spent 16 years at Genzyme, a period marked by rapid growth and expansion for the organization. She advanced within the company to become the Senior Vice President of Finance, overseeing all nine business units. Her tenure at Genzyme culminated in her instrumental role in the company's sale to Sanofi for approximately $20.1 billion.